CoChat

TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells

Open access
Kim, Jaehee, Oh, Juhyun, Peterson, Hannah M., Carlson, Jonathan C.T., Pittet, Mikael J., Weissleder, Ralph · 2022 · Advanced Biology

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Abstract

Treatment with checkpoint inhibitors can be extraordinarily effective in a fraction of patients, particularly those whose tumors are pre‐infiltrated by T cells. In others, efficacy is considerably lower, which has led to interest in developing strategies for sensitization to immunotherapy. Using various colorectal cancer mouse models, it is shown that the use of Traf2 and Nck‐interacting protein kinase inhibitors (TNIKi) unexpectedly increases tumor infiltration by PD‐1+ CD8+ T cells, thus contributing to tumor control. This appears to happen by two independent mechanisms, by inducing immunogenic cell death and separately by directly activating CD8. The use of TNIKi achieves complete tumor control in 50% of mice when combined with checkpoint inhibitor targeting PD‐1. These findings reveal immunogenic properties of TNIKi and indicate that the proportion of colorectal cancers responding to checkpoint therapy can be increased by combining it with immunogenic kinase inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/adbi.202200030

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Restrained growth of MC38 and CT26 tumors upon TNIK inhibition. In vivo treatment of NCB0486 or mebendazole in A) MC38 (n = 6 per experimental group) and B) CT26 tumor bearing mice (n = 6 per experimental group) showed reduction in tumor growth. Both TNIKi were given as monotherapy. Data are presented as mean ± standard deviation. Student’s t-test was used for statistical analysis at each time point of tumor size measurement (*<0.05, **<0.005, ***<0.0005).
Figure 1. Restrained growth of MC38 and CT26 tumors upon TNIK inhibition. In vivo treatment of NCB0486 or mebendazole in A) MC38 (n = 6 per experimental group) and B) CT26 tumor bearing mice (n = 6 per experimental group) showed reduction in tumor growth. Both TNIKi were given as monotherapy. Data are presented as mean ± standard deviation. Student’s t-test was used for statistical analysis at each time point of tumor size measurement (*<0.05, **<0.005, ***<0.0005).CC BY · PubMed Central
Figure 2. Serial profiling of mouse tumors undergoing TNIKi treatments. Multiplexed cellular analysis of tumor fine needle aspirate (FNA) was performed using FAST imaging (FAST-FNA). Cellular samples were obtained on days 0, 3, 6, and 9 of TNIKi treatment. A) Representative images of tumor cells, TNIK-expressing cells, CD8+ cells in a FNA sample and examples of cell identification analysis are shown (scale bar: 100 μm). GFP-expressing MC38 cells were implanted and the tumor cells were detected by FAST-labeled anti-GFP antibody. Cell identification was performed according to the algorithm shown in Figure S6 (Supporting Information). B) TNIK expression level in tumor cells and the frequency of CD8+ T-cells were quantified at each time point of FNA collection (n = 3 per group). GFP signal was used to identify MC38 tumor cells expressing H2B-GFP. CD8+ T-cells were identified by the following maker combination: CD45+ CD3+ CD8+ (detailed cell classification information outlined in Figure S5, Supporting Information). Additional FNA analysis is shown in Figure S7 (Supporting Information). Each data point in (B) is presented with mean ± standard deviation. One-way ANOVA with Dunnett’s multiple comparisons tests were used for statistical analyses (*<0.05, **<0.005, ***<0.0005, NS: not significant).
Figure 2. Serial profiling of mouse tumors undergoing TNIKi treatments. Multiplexed cellular analysis of tumor fine needle aspirate (FNA) was performed using FAST imaging (FAST-FNA). Cellular samples were obtained on days 0, 3, 6, and 9 of TNIKi treatment. A) Representative images of tumor cells, TNIK-expressing cells, CD8+ cells in a FNA sample and examples of cell identification analysis are shown (scale bar: 100 μm). GFP-expressing MC38 cells were implanted and the tumor cells were detected by FAST-labeled anti-GFP antibody. Cell identification was performed according to the algorithm shown in Figure S6 (Supporting Information). B) TNIK expression level in tumor cells and the frequency of CD8+ T-cells were quantified at each time point of FNA collection (n = 3 per group). GFP signal was used to identify MC38 tumor cells expressing H2B-GFP. CD8+ T-cells were identified by the following maker combination: CD45+ CD3+ CD8+ (detailed cell classification information outlined in Figure S5, Supporting Information). Additional FNA analysis is shown in Figure S7 (Supporting Information). Each data point in (B) is presented with mean ± standard deviation. One-way ANOVA with Dunnett’s multiple comparisons tests were used for statistical analyses (*<0.05, **<0.005, ***<0.0005, NS: not significant).CC BY · PubMed Central
Figure 3. Changes in the intra-tumoral immune phenotype after TNIKi treatment in MC38 tumors. A) Tumors were harvested at day 9 of treatment for flow cytometry analysis for endpoint analyses. With TNIK inhibition in the MC38 model, tumoral infiltration of CD8+ T-cells was significantly increased as seen in the serial analysis in Figure 2 and Figure S7 (Supporting Information), whereas such a change was not detected in lymph nodes or spleens of the same tumor-bearing mice. B) The number of PD-1+ CD8+ T-cell was increased indicating potential up-regulation of immune checkpoint pathway signaling. C) The number of IFN-γ+ CD8+ T-cells was also increased, indicating that a fraction of the CD8+ T-cells possess effector function. D) The CD8+ T-cell/Treg ratio was also increased with TNIK inhibition. Each data point in (B–F) is presented with mean ± standard deviation. One-way ANOVA with Dunnett’s multiple comparisons tests were used for statistical analyses (n = 6 per experimental group; *<0.05, **<0.005, ***<0.0005, NS: not significant).
Figure 3. Changes in the intra-tumoral immune phenotype after TNIKi treatment in MC38 tumors. A) Tumors were harvested at day 9 of treatment for flow cytometry analysis for endpoint analyses. With TNIK inhibition in the MC38 model, tumoral infiltration of CD8+ T-cells was significantly increased as seen in the serial analysis in Figure 2 and Figure S7 (Supporting Information), whereas such a change was not detected in lymph nodes or spleens of the same tumor-bearing mice. B) The number of PD-1+ CD8+ T-cell was increased indicating potential up-regulation of immune checkpoint pathway signaling. C) The number of IFN-γ+ CD8+ T-cells was also increased, indicating that a fraction of the CD8+ T-cells possess effector function. D) The CD8+ T-cell/Treg ratio was also increased with TNIK inhibition. Each data point in (B–F) is presented with mean ± standard deviation. One-way ANOVA with Dunnett’s multiple comparisons tests were used for statistical analyses (n = 6 per experimental group; *<0.05, **<0.005, ***<0.0005, NS: not significant).CC BY · PubMed Central
Figure 4. CD8+ T-cells play a role in the TNIKi-mediated tumor control. A) To examine the causal effect of CD8+ T-cell infiltration on the tumor control of TNIK inhibition, we performed CD8 depletion studies in MC38 tumor-bearing mice. We also monitored the tumor growth in RAG-1null mice with treatment of NCB or MBZ to further confirm the involvement of adaptive immune system in TNIKi-mediated tumor control. B) CD8 depletion accelerated the tumor growth of MC38 in mice treated with NCB or MBZ, abrogating the tumor control effect of TNIK inhibition. CD8 depletion also accelerated tumor growth in vehicle control group as expected. Statistical analysis was done between isotype control and CD8 depletion groups for NCB-treated, MBZ-treated, or untreated mice (n = 5 per group). C) Images of representative MC38 tumors in immunocompetent WT mice (top) and immunodeficient RAG-1null mice (bottom) with or without TNIK inhibition are shown. D) In RAG-1null mice, the tumor control of TNIK inhibition was significantly reduced as compared to that in WT mice (n = 6 per group). Data are presented as mean ± standard deviation. Student’s t-test was used for statistical analysis at each time point of tumor size measurement (*<0.05, **<0.005, ***<0.0005).
Figure 4. CD8+ T-cells play a role in the TNIKi-mediated tumor control. A) To examine the causal effect of CD8+ T-cell infiltration on the tumor control of TNIK inhibition, we performed CD8 depletion studies in MC38 tumor-bearing mice. We also monitored the tumor growth in RAG-1null mice with treatment of NCB or MBZ to further confirm the involvement of adaptive immune system in TNIKi-mediated tumor control. B) CD8 depletion accelerated the tumor growth of MC38 in mice treated with NCB or MBZ, abrogating the tumor control effect of TNIK inhibition. CD8 depletion also accelerated tumor growth in vehicle control group as expected. Statistical analysis was done between isotype control and CD8 depletion groups for NCB-treated, MBZ-treated, or untreated mice (n = 5 per group). C) Images of representative MC38 tumors in immunocompetent WT mice (top) and immunodeficient RAG-1null mice (bottom) with or without TNIK inhibition are shown. D) In RAG-1null mice, the tumor control of TNIK inhibition was significantly reduced as compared to that in WT mice (n = 6 per group). Data are presented as mean ± standard deviation. Student’s t-test was used for statistical analysis at each time point of tumor size measurement (*<0.05, **<0.005, ***<0.0005).CC BY · PubMed Central
Figure 5. Vaccination with TNIKi-treated cells prevents tumor growth. A) Outline of the experimental scheme. C57BL/6 mice were exposed to MC38 tumor cells that had been killed in vitro by NCB or MBZ. Control mice received PBS or MC38 cells killed in vitro by multiple freeze/thaw (FT) cycles (n = 4, 12 tumors per group). Eight days later, these cohorts of mice were all injected with live MC38 cells. B) Tumor cells treated with NCB or MBZ in vitro showed elevated expression of HMGB1 and CALR, markers indicating immunogenic cell death (scale bar: 25 μm). C,D). Tumor-free probability and the tumor volume at day 25 of tumor challenge was quantified in the animal groups that received MBZ-treated cells (green), NCB-treated cells (pink), cells underwent freeze/thaw cycles (blue), or PBS (black). MC38 cells developed much more slowly in mice that had been previously exposed to NCB-killed MC38 cells than the control groups. Likewise, MC38 cells were unable to develop visible tumors in mice previously exposed to MBZ-killed MC38 cells.
Figure 5. Vaccination with TNIKi-treated cells prevents tumor growth. A) Outline of the experimental scheme. C57BL/6 mice were exposed to MC38 tumor cells that had been killed in vitro by NCB or MBZ. Control mice received PBS or MC38 cells killed in vitro by multiple freeze/thaw (FT) cycles (n = 4, 12 tumors per group). Eight days later, these cohorts of mice were all injected with live MC38 cells. B) Tumor cells treated with NCB or MBZ in vitro showed elevated expression of HMGB1 and CALR, markers indicating immunogenic cell death (scale bar: 25 μm). C,D). Tumor-free probability and the tumor volume at day 25 of tumor challenge was quantified in the animal groups that received MBZ-treated cells (green), NCB-treated cells (pink), cells underwent freeze/thaw cycles (blue), or PBS (black). MC38 cells developed much more slowly in mice that had been previously exposed to NCB-killed MC38 cells than the control groups. Likewise, MC38 cells were unable to develop visible tumors in mice previously exposed to MBZ-killed MC38 cells.CC BY · PubMed Central
Figure 6. TNIKi-induced CD8+ T cell infiltration can potentiate immune checkpoint blockade. A) Flow cytometry analyses indicate that PD-1 level in CD8+ T-cells increase with TNIKi treatment providing a rationale for anti-PD1 combination treatment. B) Anti-PD-1 treatment administered in combination with TNIKi (right) resulted in greater tumor regression in a fraction of MC38 mice than TNIKi monotherapy (left) (n = 6 per group). C) Working model of the immunogenicity of TNIKi monotherapy and its role in successful TNIKi/ICB combination therapy. Data are presented as mean ± standard deviation. Student’s t-test was used for statistical analysis at each time point of tumor size measurement (*<0.05, **<0.005, ***<0.0005)
Figure 6. TNIKi-induced CD8+ T cell infiltration can potentiate immune checkpoint blockade. A) Flow cytometry analyses indicate that PD-1 level in CD8+ T-cells increase with TNIKi treatment providing a rationale for anti-PD1 combination treatment. B) Anti-PD-1 treatment administered in combination with TNIKi (right) resulted in greater tumor regression in a fraction of MC38 mice than TNIKi monotherapy (left) (n = 6 per group). C) Working model of the immunogenicity of TNIKi monotherapy and its role in successful TNIKi/ICB combination therapy. Data are presented as mean ± standard deviation. Student’s t-test was used for statistical analysis at each time point of tumor size measurement (*<0.05, **<0.005, ***<0.0005)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 14

Metadata

Authors
Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R.
Affiliations
  • Massachusetts General Hospital (US)
  • Harvard University (US)
  • Center for Systems Biology Massachusetts General Hospital 185 Cambridge St, CPZN 5206 Boston MA 02114 USA
Corresponding author
Weissleder, Ralph
Venue
Advanced Biology
Publisher
Wiley
Published
2022-06-08
Volume
6
Issue
8
Pages
e2200030-e2200030
ISSN
2701-0198 (ISSN-L)
OpenAlex
W4281735166
Cited by
14
References
43
Citations by year
2026: 2 · 2025: 5 · 2024: 6 · 2023: 1
FWCI
1.26
Type
journal article
Language
en
Open access
Locations
  • Advanced Biology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • SERVAL (Université de Lausanne) (publishedVersion, cc-by)
  • PubMed Central (acceptedVersion, cc-by)
  • IRIS (submittedVersion, cc-by)
  • Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
Funders
Korea Health Industry Development Institute
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
TNIK, immune checkpoint inhibitors, PD-1, CD8+ T cells, tumor-infiltrating T cells, immunogenic cell death, colorectal cancer, immunotherapy sensitization, kinase inhibitors, tumor immune microenvironment
MeSH terms
Animals, Disease Models, Animal, Immunotherapy, Colorectal Neoplasms, CD8-Positive T-Lymphocytes, Protein Kinase Inhibitors, Mice, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells. https://app.cochat.ai/papers/10.1002/adbi.202200030
The paper
Kim, J., Oh, J., Peterson, H. M., Carlson, J. C. T., Pittet, M. J., & Weissleder, R. (2022). TNIK Inhibition Has Dual Synergistic Effects on Tumor and Associated Immune Cells. Advanced Biology. https://doi.org/10.1002/adbi.202200030

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.